Predictive biomarkers for EGFR tyrosine kinase inhibitors in treatment of advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials
ZY Yang1, C Mao1, DY Zheng2, JL Tang1
1 Division of Epidemiology, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong
2 Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China
1. Of the four potential predictive biomarkers studied, epidermal growth factor receptor (EGFR) gene mutations are the most powerful predictor of the efficacy of EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer. They should be tested prior to treatment to select patients who are more likely to benefit from EGFR tyrosine kinase inhibitors.
2. Chemotherapy is a better choice than EGFR tyrosine kinase inhibitors in patients with wild-type EGFR.